A PHASE 2 OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF ABT-199 (GDC-0199) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SUBJECTS WITH RELAPSE OR REFRACTORY TO B-CELL RECEPTOR SIGNALING PATHWAY INHIBITOR THERAPY: